TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06663956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a patient self-reporting applet
Description: We propose to develop a patient self-reporting applet that is easy to use and simple to operate. The program is embedded with questionnaires related to cancer pain and quality of life assessment, so that patients can fill out the questionnaires to report their symptoms and changes in their conditions to primary care doctors in a timely manner. At the same time, the background of the program will monitor the patient's indicators in real time. When the patient's pain reaches moderate-to-severe level, or when the patient experiences side effects of drugs, or when the patient's adherence to medication is poor, the primary care doctor can immediately receive relevant alerts through the app, so as to intervene in the patient's cancer pain treatment. When the patient has an alarm value, primary care doctors can provide feedback to doctors in higher-level hospitals and implement comprehensive and standardized treatment for cancer pain patients.
Study: NCT06250335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV
Study: NCT06036836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: favezelimab/pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: favezelimab/pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Oral administration of capsule
Study: NCT05607004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Z)-endoxifen
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Z)-endoxifen
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Z)-endoxifen
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Study: NCT06036836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Oral administration of capsule
Study: NCT06295783

Intervention type: OTHER
Intervention: MDASI-HN
Description: Given by Questionnaire

Intervention type: OTHER
Intervention: EORTC QLQ-C30
Description: Given by Questionnaire

Intervention type: OTHER
Intervention: EORTC HN35
Description: Given by Questionnaire
Study: NCT04964934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally
Study: NCT05607004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Z)-endoxifen
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Z)-endoxifen
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Z)-endoxifen
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: exemestane tablets 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: goserelin 3.6 mg subcutaneous implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: goserelin 3.6 mg subcutaneous implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: goserelin 3.6 mg subcutaneous implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: goserelin 3.6 mg subcutaneous implant
Study: NCT04964934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9833 Placebo
Description: Dosage formulation: AZD9833 placebo tablets will be administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Dosage formulation: anastrozole tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole placebo
Description: Dosage formulation: anastrozole placebo tablets will be administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Dosage formulation: letrozole tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole placebo
Description: Dosage formulation: letrozole placebo tablets will be administered orally.
Study: NCT06663280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital health assistant ADELE
Description: The digital health assistant ADELE Blood Pressure A0007 (ADELE for short) improves the daily lives of patients with high blood pressure and enhances patient care. Participants in the intervention group were provided with ADELE to use during the study period for voice-based recording, interpretation and classification of their vital signs and body conditions.
Study: NCT06664047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OTT ACLR
Description: Patients in this group will undergo a reconstruction with the OTT technique which includes an intra-articular component and an extra-articular one, functioning as a LET.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACLR LET
Description: Patients in this group will undergo a reconstruction with the conventional ACL technique accompanied by a routine LET, obtained from the iliotibial band.
Study: NCT06662487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants in the experimental group will perform free weight resistance training sessions focused on push, pull, and leg movement patterns. The program will last for 10 weeks, progressively increasing in load and intensity. The intervention will be designed to improve the participants' physical strength and observe how these changes affect their cognitive performance.
Study: NCT06665438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline (Placebo)
Description: the 18 ml of normal saline will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: the 18ml 0.25% bupivacaine. will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
Study: NCT04964934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally
Study: NCT06665438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.
Study: NCT06665139

Intervention type: DIAGNOSTIC_TEST
Intervention: muscle thickness
Description: Pain intensity will be measured with visual analog scale, sonographic severity grade of shoulder impingement syndrome, muscle thickness of serratus anterior muscle, upper trapezius and middle trapezius with USG in patients diagnosed with impingement and meeting the criteria and healthy volunteers.

Intervention type: DIAGNOSTIC_TEST
Intervention: muscle thickness
Description: Pain intensity will be measured with visual analog scale, sonographic severity grade of shoulder impingement syndrome, muscle thickness of serratus anterior muscle, upper trapezius and middle trapezius with USG in patients diagnosed with impingement and meeting the criteria and healthy volunteers.
Study: NCT06665347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: The participants will receive progressive muscle relaxation for 8 weeks. The muscles of the hand, arm, face, shoulder and neck, chest, abdomen, back, thigh and hip, legs and feet will be contracted and relaxed in sequence. The contraction time is 5 seconds (s), and the relaxation time is 10s.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: The participants will receive progressive muscle relaxation for 8 weeks. The muscles of the hand, arm, face, shoulder and neck, chest, abdomen, back, thigh and hip, legs and feet will be contracted and relaxed in sequence. The contraction time is 5 seconds (s), and the relaxation time is 10s.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The participants will receive yoga for 30 minutes/session, 3 sessions/week for 8 weeks. The session will begin with 5 minutes for warming up. Twenty minutes of wind relieving position (pavanmuktasana), corpse position (savasana), standing side stretch position, seated forward bend (paschimothanasana), cobra position (bhujangasana), and chair position (utkatasana). Five minutes of cooling down.
Study: NCT06666647

Intervention type: PROCEDURE
Intervention: Treatment by ambulance or helicopter services with response times
Description: Prehospital treatment by ambulance and/or helicopter services personnel of patients in acute conditions
Study: NCT06666101

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Long chain polyunsaturated Omega-3
Description: 2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Long chain polyunsaturated Omega-3
Description: 2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Long chain polyunsaturated Omega-3
Description: 2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil
Study: NCT06665243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-enhanced horticultural activities
Description: The indoor technology-enhanced horticultural activities will be delivered to people with dementia and their family caregivers through a smart grower. The smart grower is a hydroponic indoor grower that creates a controllable environment with auto optimization for growing healthy plants, fresh vegetables, herbs, and fruits. A mobile app will be connected to the grower for controlling the growing environment (e.g., lighting, watering), tracking the progress of the plants, and guiding the older people with dementia and their family caregivers in conducting the horticultural activities. The program will consist of eight face-to-face (F-T-F) horticultural activity training sessions for groups of 6-8 participants. The indoor program contains various horticultural, cognitive, and multisensory stimulation activities, such as asking PWD and family caregivers to record the sense of touch and odor when caring for the plants and to observe the various changes in the plants using the smart grower.
Study: NCT06666634

Intervention type: DRUG
Group type: OTHER
Intervention: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
Description: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
Study: NCT06666790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scan with elastic scattering spectroscopy device to assess risk of malignancy
Description: Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
Study: NCT06668415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydro dilation
Description: The hydro dilation injections comprises of Depomedrol 80mg and normal saline 0.9%. It is performed under fluoroscopic guidance by the orthopedic surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydro dilation
Description: The hydro dilation injections comprises of Depomedrol 80mg and normal saline 0.9%. It is performed under fluoroscopic guidance by the orthopedic surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spencer muscle energy technique
Description: Spencer muscle energy technique is a seven 7 step procedure which consists of shoulder extension with elbow flexed, shoulder flexion with elbow flexed, circumduction with compression, circumduction with traction, Abduction then adduction with external rotation and glenohumeral pump. Following the complete action, patients will be encouraged to use their muscles for 3 to 5 seconds against little resistance provided by the therapist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Stretching
Description: The low intensity stretches will be given in supine for all the movements ie Flexion ,Abduction , Internal Rotation and External Rotation for 5 repititions with 30 sec hold.
Study: NCT06667206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licenced Measles-Rubella vaccine
Description: Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licenced Measles-Rubella vaccine
Description: Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licenced Measles-Rubella vaccine
Description: Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme
Study: NCT06667570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SALFOAM 3%
Description: * Drug: Polidocanol 3%~* Device: Lidstop®

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: * Drug: Polidocanol 3%~* Device: Standard compression with dental roll and elastic stockings
Study: NCT06610630

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Bowel Preparation Using AI-Driven Smartphone Applications
Description: Assessment of Bowel Preparation Using AI-Driven Smartphone Applications
Study: NCT06666803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FNB sampling
Description: A supplementary FNB will be performed during the EUS procedure. Sample will be processed to obtain organoids and assess their morphological, proliferative and genetics characteristics.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood withdrawal will be performed during the EUS procedure. Sample will be processed to assess organoids morphological, proliferative and genetics characteristics.
Study: NCT06666894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: subjects consumed 100 % of their energy needs in an 8-h period of time each day, with their caloric intake divided into three meals consumed at 1 p.m., 4 p.m., and 8 p.m. The remaining 16 h per 24-h period made up the fasting period. Subjects in the ND group consumed 100 % of their energy needs divided into three meals consumed at 8 a.m., 1 p.m., and 8 p.m. all patients will be subjected to 30 minutes mild aerobic exercise on treadmill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary approach to stop hypertension (DASH)
Description: The USDA's 2015-2020 Dietary Guidelines for Americans recommend a healthy eating pattern, including a variety of vegetables, fruits, whole grains, fat-free dairy, protein, and oils. Limit saturated fats, trans fats, added sugars, and sodium to less than 10% daily calories, 10% saturated fat daily calories, and 2,300 mg sodium per day.
Study: NCT06668558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Dosing is 75 mg/m2 x 7 days (Q28days) After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Dosing is 75 mg/m2 x 7 days (Q28days) After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dosing: 400 mg daily After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dosing: 400 mg daily After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)
Study: NCT06668844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic direct Draf IIa
Description: Endoscopic direct Draf IIa (Carolyn' window approach) frontal sinusotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic angled Draf IIa
Description: Group BFrontal sinusotomy using angled endoscopeand instruments
Study: NCT06666621

Intervention type: DRUG
Group type: OTHER
Intervention: Normal saline infusion
Description: After assessment of response to lumbar medial branch block, 8 ml normal saline will be infused through IV over several minutes. 10 minutes will pass, and response to lumbar medial branch block procedure will be re-assessed.~After this step, naloxone infusion will occur (see next intervention)

Intervention type: DRUG
Group type: OTHER
Intervention: Naloxone infusion
Description: After infusion of normal saline and re-assessment of response to lumbar medial branch block procedure, 8 milligrams of naloxone will be infused over several minutes. Then after 10 minutes, response to lumbar medial branch block procedure will be re-reassessed for the final time.
Study: NCT06664983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC chemotherapy
Description: The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab combined TPC chemotherapy
Description: Cadonilimab was intravenously given at dose of 10 mg/kg on day 1. The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
Study: NCT06666478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol at workspace
Description: The exercise protocol at Workspace begins in a sitting position with spinal mobility exercises that mobilize the hips, lumbar spine, thoracic spine, and cervical spine, accompanied by progressive activation of the peripheral joints in the upper limbs. This is followed by multiaxial functional exercises for the trunk and upper limbs, which combine various movements (e.g., lateral bending and twisting) that simulate the positions employees assume while working.~Subsequently, exercises are performed in an upright position, focusing on stretching and mobilizing the joints and nervous tissue to promote relaxation and release. Coordination, fluid movement, and controlled breathing are emphasized to help workers develop and maintain a stable core while on the job. These principles are essential for workers who are frequently exposed to stressors and physical exertion, as they seek to improve the quality of their movements-namely, smoothness, rhythm, and appropriate speed-while at work.
Study: NCT06618690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: A supervised training plan will be carried out for 12 weeks with a frequency of 3 sessions per week with a duration of 60 minutes, an ideal estimate according to the meta-analysis of Montaño-Rojas et al. The first two weeks the group exercises will be performed to familiarize the participants with the exercises and then each participant will perform them at home with a review every two weeks to assess the increase of the load.~The exercises and loads included in this treatment plan have been designed and modified based on previous clinical trials. The training plan will work upper limbs, lower limbs and trunk. All sessions begin with a general warm-up, which will be previously instructed to the participants, in which the heart rate will be increased (see Multimedia Appendix 1). After a two-minute break, the specific block of each session will begin (see Table 1 and Multimedia Appendix 1). All exercises will be performed with dumbbells, elastic bands and a ball.
Study: NCT06617949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Patient Controlled Analgelsic
Description: This group will be administered epidural PCA as a modality for pain control post cesarian section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural local anesthetic infusion
Description: Epidural group will receive pain control via a local anesthetic intermediate bolus infusion
Study: NCT06620640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.
Description: Nigth stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.
Description: Nigth stimulation